Skip to content
Datasets/TCGA-BRCA

Breast Invasive Carcinoma

MixedProject-curated
TCGAAvailable from GDC and IDC

1,098 breast tumors measured twelve ways across GDC and IDC, with treatment outcome on 64% of cases - the most reused dataset in this corpus and still the reference cohort for method development.

Can it answer your research question?

6 of 6 supported
  • Overall survival

    Supported

    Vital status and time are populated; median follow-up 2.3 years; 1,096 cases with follow-up; endpoints: overall survival, progression-free interval.API

  • Progression or recurrence

    Supported

    A time to event is derivable: progression-free interval; progression_or_recurrence is informative for 9% of cases.API

  • Treatment response

    Supported

    disease_response is populated for 97% of cases; criteria: complete response, progressive disease.API

  • Which drug was given

    Supported

    therapeutic_agents is recorded for 71% of cases.API

  • Stage-adjusted modelling

    Supported

    ajcc_pathologic_stage is informative for 99% of cases.API

  • Analysis by race or ethnicity

    Supported

    Race is informative for 91% of cases.API

Judged from the repository’s own field completeness (thresholds). “Not measured” means we have not probed that field for this record, not that the data lack it.

At a glance

Every percentage is the repository’s own record of what is filled in
CasesAPI2
1,098
Measurement types
12
71,423 files, 568 TB
Follow-upAPI
2.3 years
for 1,096 of 1,098 cases; overall survival, progression-free interval
Treatment responseAPI
Recorded
complete response, progressive disease, stable disease

SubjectCALC

Breast

As filed by the repository

Cystic, Mucinous and Serous NeoplasmsAdenomas and AdenocarcinomasFibroepithelial NeoplasmsBasal Cell NeoplasmsDuctal and Lobular NeoplasmsEpithelial Neoplasms, NOSSquamous Cell NeoplasmsComplex Epithelial NeoplasmsAdnexal and Skin Appendage NeoplasmsBreast

Who is in the cohortAPI

A usable value“Not reported” or “unknown”No value recorded
  • Sex1,085 female · 12 male · 1 no value recorded
  • Race757 white · 183 black or african american · 61 asian · 1 1 other · 95 not reported · 1 no value recorded
  • Ethnicity884 not hispanic or latino · 39 hispanic or latino · 166 not reported · 8 unknown · 1 no value recorded
  • Vital status945 alive · 152 dead · 1 no value recorded

Age at diagnosis

Median 59, middle half 50–68, range 27–90 years across 1,082 cases.

What was measured, and on how many

12 measurement types, 3 covering the whole cohort.

  • SNP genotyping array (copy number, germline)1,098 of 1,098 · 100%
  • Clinical1,098 of 1,098 · 100%
  • DICOM medical imaging1,098 of 1,098 · 100%
  • DNA methylation array1,097 of 1,098 · >99%
  • Bulk RNA sequencing1,095 of 1,098 · >99%
  • microRNA sequencing1,079 of 1,098 · 98%
  • Whole exome sequencing1,072 of 1,098 · 98%
  • Whole-slide diagnostic images1,062 of 1,098 · 97%
  • Whole genome sequencing952 of 1,098 · 87%
  • Somatic Structural Variation927 of 1,098 · 84%
  • Reverse phase protein array881 of 1,098 · 80%
  • ATAC sequencing (chromatin accessibility)74 of 1,098 · 7%
Platform, files and data levels
AssayPlatformFilesLevels
SNP genotyping array (copy number, germline)APIillumina14,329-
ClinicalAPI2-2,288-
DICOM medical imagingAPI--DICOM series
DNA methylation arrayAPIillumina3,714-
Bulk RNA sequencingAPIillumina11,079-
microRNA sequencingAPIillumina3,621-
Whole exome sequencingAPIillumina17,050-
Whole-slide diagnostic imagesAPI2illumina1,133-
Whole genome sequencingAPI2illumina13,031-
Somatic Structural VariationAPI-3,128-
Reverse phase protein arrayAPIillumina919-
ATAC sequencing (chromatin accessibility)APIillumina75-
How complete all 29 clinical fields are - 15 informative for at least 80% of cases

A field counts as informative only when it holds a real value. “Not reported” blocks an analysis just as a missing field does. Fields marked 1:n can hold several records per case, so they show the share of cases with any record.

Informative - a usable valuePresent but uninformative - “not reported” or “unknown”Absent - no value recorded

Outcome

  • Vital statusAPI>99%
  • Cause of deathAPI0%
  • Progression or recurrenceAPI0%
  • Last known disease statusAPI0%

Follow-up

  • Disease response at follow-up1:nAPI97%
  • Progression at follow-upAPI9%
  • ECOG performance statusAPI0%

Treatment

  • Prior treatment1:nAPI>99%
  • Treatment type1:nAPI>99%
  • Treatment given1:nAPI>99%
  • Therapeutic agents1:nAPI71%
  • Treatment outcome1:nAPI64%
  • Regimen or line of therapyAPI<1%

Staging

  • AJCC pathologic stageAPI99%
  • AJCC clinical stageAPI0%

Diagnosis

  • Primary diagnosis1:nAPI>99%
  • Tissue or organ of origin1:nAPI>99%
  • Prior malignancyAPI>99%
  • Synchronous malignancyAPI>99%

Pathology

  • Morphology (ICD-O)1:nAPI>99%
  • Classification of tumor1:nAPI>99%
  • Tumor gradeAPI0%

Demographics

  • Sex at birthAPI>99%
  • RaceAPI91%
  • EthnicityAPI84%
  • Country of residenceAPI64%
  • Population groupAPI0%

Exposure

  • Tobacco smoking statusAPI0%
  • Alcohol historyAPI0%

Access

MixedSome components are open; others need approval.API

Data Access Request through dbGaP using an eRA Commons account; institutional signing official approval required

Open components
27,931 open-access files
Controlled components
43,492 controlled-access files
Typical turnaround
days to a few weeks after signing official approval
License
NIH Genomic Data Sharing Policy terms
Citation requirement
Cite the dataset accession and the program's publication guidelines; see the GDC publication policy.

What it is good for

Written and checked by a reviewer, not generated from metadata.

  1. 1. Does a new computational method reproduce established breast cancer molecular subtypes?

    Answerable as shippedn ≈ 1,080HUMAN

    Expression, methylation, copy number, microRNA and protein array data on largely the same 1,098 tumors, with subtype assignments established across hundreds of prior papers. This is the standard benchmark, and the density of prior work is the point.

    Statistical note: Because so many methods have been tuned on this cohort, strong performance here is weak evidence of generalization. Pair it with an external cohort.

    NeedsBulk RNA sequencingDNA methylationCopy numberReverse phase protein array

    A published example: PMID 23000897

  2. 2. Which molecular features are associated with response to specific systemic therapies?

    Answerable as shippedn ≈ 700HUMAN

    Therapeutic agents are recorded for 71% of cases - cyclophosphamide, tamoxifen, anastrozole, paclitaxel and doxorubicin are the commonest - and a treatment outcome field is populated for 64%. Combined with expression on 1,095 cases this supports agent-stratified response analysis.

    Statistical note: Treatment was not randomized and is confounded with stage, subtype and era of care. Any agent comparison needs explicit confounding control and should be framed as associative.

    NeedsBulk RNA sequencingTreatment recordsdiagnoses.treatments.therapeutic_agentsdiagnoses.treatments.treatment_outcome
  3. 3. Do radiology or pathology image features add prognostic information beyond molecular data?

    Needs another datasetn ≈ 1,098HUMAN

    Imaging for these same patients is held in the Imaging Data Commons and is openly downloadable, while the molecular data sit in the GDC. Joining them gives a multimodal cohort most users never realise is available.

    Statistical note: Imaging coverage is not complete across the cohort; build the intersection first and check it is not biased by site or era.

    NeedsRadiology imagingHistopathology slidesBulk RNA sequencing
  4. 4. What distinguishes long-term survivors, given a median follow-up of 27.1 months?

    Answerable as shippedn ≈ 1,097HUMAN

    Vital status is informative for 99.9% of cases and follow-up time is computable, giving a clean overall survival endpoint on a large cohort.

    Statistical note: Breast cancer events accrue over a decade or more, and the median patient here is followed under three years, although a minority reach twenty years. Late-recurrence questions are underpowered.

    NeedsClinical dataOutcome dataBulk RNA sequencing

What it cannot tell you

Written by a reviewer against the source, not inferred from what is missing.

MajorStatistical powerHUMAN

Median follow-up is 27.1 months across 1,096 of 1,098 cases, though the maximum reaches 282 months. Breast cancer, particularly hormone receptor positive disease, recurs over ten to twenty years, so the median patient is observed through only the early part of the natural history.

Affects: Late recurrence; Ten-year survival; Endocrine resistance over time

Mitigation: Use restricted mean survival time; do not extrapolate beyond observed follow-up.

MajorTreatment contextHUMAN

Treatment is observational and unrandomised, recorded retrospectively, and reflects standards of care from the late 2000s. Modern regimens including CDK4/6 inhibitors, antibody-drug conjugates and immunotherapy are absent.

Affects: Predictive biomarker claims; Contemporary treatment relevance

Mitigation: Frame findings as historical-cohort associations rather than predictive claims.

MajorPopulation coverageHUMAN

757 of 1,098 patients are recorded as white and 183 as Black or African American, with 95 not reported. Male breast cancer is present only in very small numbers.

Affects: Disparities research beyond the two largest groups; Male breast cancer

Mitigation: The 183 Black patients support some disparities work but with limited power for subtype-stratified analysis.

MinorPlatform obsolescenceHUMAN

Methylation uses HM450 and HM27 arrays and copy number uses Affymetrix SNP 6.0 - platforms no longer in routine use, which complicates integration with contemporary data.

Affects: Cross-cohort integration with modern platforms

Mitigation: Use probe-level harmonization and restrict to shared features.

MinorAccess constraintHUMAN

43,492 of 71,423 files are controlled; derived matrices are open.

Affects: Raw sequence analysis

Mitigation: Most secondary analyses run entirely on the open derived files.

Not appropriate for

  • Evaluating modern therapies such as CDK4/6 inhibitors or immunotherapy. - Treatment predates these agents; they do not appear in the cohort.HUMAN
  • Estimating breast cancer incidence or population survival. - A convenience sample from participating centres, with no denominator.HUMAN
  • Claiming a novel method generalizes on the basis of TCGA-BRCA performance alone. - The cohort has been used so extensively for method development that performance on it is partly a measure of collective overfitting.HUMAN

Who has used it

Articles that analyzed these data, counted separately from articles that only cited the paper. Only the first counts as reuse.

Analyzed the dataCALC2
2,373
accession in the methods; 100% of a 29-article sample really cited it
Declared using it
313
named in a data availability statement
Cited the paper
9,914
attention to the publication, not reuse of the data
Against expectation
As expected or above
about 412 articles expected; index 2.52

What articles did with it

Only the last row counts as reuse. Where the accession appears in an article tells us what the authors did with the data.

  • Cited the paper9,914
  • Mentioned the dataset269
  • Accession found in text0
  • Declared using it313
  • Analyzed the data2,373

Against comparable datasets

2,373 articles analyzed these data. About 412 would be expected. The expectation comes from a model of size, age, breadth and access tier.

  • Analyzed it2,373
  • Expected~412
Reuse assessment
  • Reuse is within the expected range for comparable datasets (index +2.52).

Compared against 132 datasets in this corpus with a citable accession and sufficient metadata. See Methods for the model.

Original publication

Articles that analyzed the data

Examples, not the full list. 114 articles matching this dataset's accession search were retrieved and graded individually; these are the strongest of those.

Deep-review sample: author overlap and funding were checked only for the 10 articles listed here, not for every article examined. Of the 10 that analyzed the data, 9 of the 10 we could check had no author in common with the generating team, and 0 of the 10 we could check were themselves NCI-funded. These are sample counts, not population estimates.

Community examples

Share your example

Analyses someone ran on these data end to end, each with a receipt recording when it ran, against which packages and for how long.

beginner

Which classes of analysis do this cohort's clinical records actually support, and which are ruled out before I request access?

Audit whether this dataset can answer your question

CD2S workbooks · ran 21 Sept 2026
pythonabout a minuteexecuted
Required inputs
  • A GDC project identifier
  • Network access to api.gdc.cancer.gov
Expected outputs
  • Per-field coverage table separating populated from informative values
  • Assay coverage as a percentage of the cohort
  • A yes/no verdict for six common analysis classes
  • A chart contrasting populated with informative coverage, field by field
Steps
  1. Fetch project summary and per-assay case counts
  2. Request facet counts for the clinical fields that gate common analyses
  3. Separate absent fields from fields populated with non-answers
  4. Flag one-to-many fields where per-case percentages cannot be inferred
  5. Retrieve case-level fields and test whether a survival endpoint is derivable
  6. Print a verdict for each analysis class
beginner

Which molecular and clinical factors are associated with survival?

Overall survival from open data, with the endpoint derived correctly

CD2S workbooks · ran 21 Sept 2026
pythonabout two minutesexecuted
Required inputs
  • Open GDC clinical records, no account required
  • lifelines, pandas, numpy
Expected outputs
  • Kaplan-Meier estimates with survival at 12, 36 and 60 months
  • Log-rank test between stage groups
  • Multivariable Cox model with concordance
  • A Kaplan-Meier plot of overall survival, stratified by stage at diagnosis
Steps
  1. Retrieve case-level clinical fields including all three follow-up locations
  2. Derive time and event, guarding against GDC sentinel values
  3. Report how many cases are dropped and why
  4. Fit Kaplan-Meier and a stage-stratified log-rank test
  5. Fit a multivariable Cox model adjusting for age and stage
advanced

Which cohorts have both imaging and molecular data on the same patients, and how many patients actually carry both?

Join the same patients across two NCI repositories

CD2S workbooks · ran 21 Sept 2026
pythonabout two minutesexecuted
Required inputs
  • Open GDC and IDC APIs, no account required
  • pandas
Expected outputs
  • Patient-level intersection between a GDC project and an IDC collection
  • Counts of molecular-only, imaging-only and joined patients
  • A map of every cohort present in both repositories
  • A chart comparing molecular and imaging patient counts per linkable cohort
Steps
  1. Retrieve patient identifiers from the GDC project
  2. Query IDC's public SQL endpoint for the collection's patient identifiers
  3. Intersect on the shared barcode and quantify the overlap
  4. Sweep every GDC project against every IDC collection

Start here

Starter code generated from this record’s own identifiers, then the access steps.

Get the data in code

GDC: list open files and download thempython

Open-access files need no account. Controlled files need an approved dbGaP request and a token passed to gdc-client.

import json, requests

PROJECT = "TCGA-BRCA"
filters = {"op": "and", "content": [
    {"op": "in", "content": {"field": "cases.project.project_id", "value": [PROJECT]}},
    {"op": "in", "content": {"field": "access", "value": ["open"]}},
]}
params = {"filters": json.dumps(filters),
          "fields": "file_id,file_name,data_category,data_type,file_size",
          "size": "10000", "format": "JSON"}
files = requests.get("https://api.gdc.cancer.gov/files", params=params, timeout=60).json()["data"]["hits"]
print(len(files), "open files")

# Write a manifest and fetch with the GDC client (https://gdc.cancer.gov/access-data/gdc-data-transfer-tool)
with open("manifest.txt", "w") as fh:
    fh.write("id\n" + "\n".join(f["file_id"] for f in files))
# $ gdc-client download -m manifest.txt
GDC: clinical table for every casepython
import json, requests

filters = {"op": "in", "content": {"field": "project.project_id", "value": ["TCGA-BRCA"]}}
params = {"filters": json.dumps(filters), "size": "5000", "format": "TSV",
          "fields": ",".join([
              "submitter_id", "demographic.vital_status", "demographic.days_to_death",
              "diagnoses.days_to_last_follow_up", "diagnoses.ajcc_pathologic_stage",
              "diagnoses.treatments.treatment_type", "diagnoses.treatments.treatment_outcome"])}
tsv = requests.get("https://api.gdc.cancer.gov/cases", params=params, timeout=60).text
open("TCGA-BRCA_clinical.tsv", "w").write(tsv)
IDC: pull the DICOM collection with idc-indexpython

pip install idc-index. Images are public; the package uses s5cmd under the hood.

from idc_index import IDCClient

COLLECTION = "tcga_brca"
client = IDCClient()

series = client.index[client.index["collection_id"] == COLLECTION]   # one row per DICOM series
print(len(series), "series,", series["PatientID"].nunique(), "patients,",
      round(series["series_size_MB"].sum() / 1024, 1), "GB")
print(series["Modality"].value_counts().to_dict())

# Everything above is an index lookup and costs nothing. Uncomment to pull the pixels;
# the client refuses up front if the disk cannot hold them.
# client.download_from_selection(collection_id=COLLECTION, downloadDir="./tcga_brca")
This page as data: limitations firstbash
curl -s https://cd2s.vercel.app/data/datasets/gdc-tcga-brca.json | python3 -c '
import json, sys
r = json.load(sys.stdin)
for l in r["limitations"]:
    print(l["severity"].upper(), "-", l["statement"][:120])
print("survival endpoint:", r["longitudinal"]["has_survival_endpoint"], "| treatment response:", r["longitudinal"]["has_treatment_response"])'

Access steps

  1. 1
    Download open derived matrices from the GDCFor people1 hour

    Expression, copy number, methylation and clinical files need no account.

    curl -s 'https://api.gdc.cancer.gov/files' --get \
      --data-urlencode 'filters={"op":"and","content":[
        {"op":"in","content":{"field":"cases.project.project_id","value":["TCGA-BRCA"]}},
        {"op":"in","content":{"field":"access","value":["open"]}},
        {"op":"in","content":{"field":"data_type","value":["Gene Expression Quantification"]}}]}' \
      --data-urlencode 'fields=file_id,file_name,cases.submitter_id' \
      --data-urlencode 'size=2000&format=TSV' > brca_expression_files.tsv
    
    https://portal.gdc.cancer.gov/projects/TCGA-BRCA
  2. 2
    Add the imaging from the Imaging Data Commons if you need itFor people1-2 hours

    Same patients, different repository, also open. Most users never make this join.

    https://portal.imaging.datacommons.cancer.gov/explore/?collection_id=tcga_brca
  3. 3
    Request controlled access only if you need sequence-level dataFor peopledays to a few weeks

    Requires: eRA Commons account, institutional signing official approval

    https://gdc.cancer.gov/access-data/obtaining-access-controlled-data
  4. 4
    Query the project from code, with no credentialsFor agents

    The file index is public even where files are not, so an agent can size the cohort before anyone requests access.

    curl -s 'https://api.gdc.cancer.gov/files' --get \
      --data-urlencode 'filters={"op":"in","content":{"field":"cases.project.project_id","value":["TCGA-BRCA"]}}' \
      --data-urlencode 'fields=file_id,file_name,data_type' \
      --data-urlencode 'size=10000' --data-urlencode 'format=TSV'
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

  5. 5
    Pass the token when the agent needs controlled filesFor agents

    Without a token, an API query may return only the open subset. Compare returned counts with the record before treating them as the whole cohort.

    Requires: GDC authentication token

    curl -H "X-Auth-Token: $GDC_TOKEN" https://api.gdc.cancer.gov/data/<file_id>
    https://docs.gdc.cancer.gov/API/Users_Guide/Getting_Started/

    Generated from repository policy. Check the linked policy before downloading.

Provenance

All of it, and more, is in this record’s JSON.

Identifiers

Versions and verification

Released
1 Jan 2013
Metadata retrieved
18 Sept 2026
Review status
Project-curatedCD2S project curation on 18 Sept 2026
Data generation funding
Funded data generation

Funding

Awards resolved through NIH RePORTER. Awards that paid to generate these data are listed apart from awards that paid to reuse them. Both are returns on NCI investment, but different ones.

Funded data generation

  • U24CA144025Harvard Genome Characterization CenterRaju S. KucherlapatiFY2009-2016API
  • U24CA143883Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)Rehan Akbani, GORDON B. MILLSFY2009-2016API
  • U24CA143882The USC-JHU Cancer Epigenome Characterization CenterSTEPHEN B. BAYLIN, Daniel Joseph WeisenbergerFY2009-2016API
  • U24CA143867Genome Characterization Center (GCC)Stacey Gabriel, Matthew L. MeyersonFY2009-2016API
  • U24CA143866Cancer transcriptome characterization using massively parallel DNA sequencingMarco Antonio MarraFY2009-2015API
  • U24CA143858UCSC-Buck Inst. Genome Data Analysis Center for TCGA Research Network (GDAC)Christopher Benz, DAVID H HAUSSLERFY2009-2016API
  • U24CA143848Gene Expression Patterns in Human Tumors Identified Using Transcript SequencingDavid N Hayes, CHARLES M PEROUFY2009-2016API
  • U24CA143845The Cancer Genome Atlas Data Analysis CenterLYNDA CHIN, GAD A GETZFY2009-2016API
  • U24CA143840MSKCC Center for Translational Cancer Genomic AnalysisMarc Ladanyi, CHRIS SANDERFY2009-2016API
  • U24CA143835Center for Systems Analysis of the Cancer RegulomeILYA SHMULEVICHFY2009-2016API

and 4 more

For softwarerecord JSON